Compare IDCC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDCC | BLTE |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.0B |
| IPO Year | 2007 | 2021 |
| Metric | IDCC | BLTE |
|---|---|---|
| Price | $344.56 | $163.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $412.50 | $198.00 |
| AVG Volume (30 Days) | ★ 251.5K | 132.3K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.51 | N/A |
| Revenue | ★ $307,404,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.38 | $492.11 |
| P/E Ratio | $59.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $249.14 | $60.00 |
| 52 Week High | $412.60 | $200.00 |
| Indicator | IDCC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 76.89 | 57.68 |
| Support Level | $315.71 | $153.54 |
| Resistance Level | $336.25 | $161.17 |
| Average True Range (ATR) | 10.92 | 5.93 |
| MACD | 8.07 | 0.23 |
| Stochastic Oscillator | 90.82 | 81.36 |
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.